Sign Out
Pregnancy: Vivitra should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus. In the post marketing setting, cases of oligohydramnios have been reported in pregnant women receiving trastuzumab. It is not known whether trastuzumab can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity. Reported animal reproduction studies revealed no evidence of impaired fertility or harm to the fetus.
Nursing Mothers: It is not known whether trastuzumab is secreted in human milk. As human IgG is secreted into human milk, and the potential for harm to the infant is unknown, breast-feeding should be avoided during Vivitra therapy.
